US 9,808,486 B2
Administration of kynurenine depleting enzymes for tumor therapy
George Georgiou, Austin, TX (US); and Everett Stone, Austin, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Aug. 29, 2014, as Appl. No. 14/473,040.
Claims priority of provisional application 61/872,132, filed on Aug. 30, 2013.
Claims priority of provisional application 61/986,366, filed on Apr. 30, 2014.
Prior Publication US 2015/0064154 A1, Mar. 5, 2015
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); C12N 9/14 (2006.01); A61K 38/46 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 38/46 (2013.01); C12N 9/14 (2013.01); C12Y 307/01003 (2013.01); A61K 38/00 (2013.01)] 16 Claims
 
1. A method of treating a subject having a tumor comprising administering to the subject an effective amount of a pharmaceutical formulation comprising:
(i) a kynureninase polypeptide comprising the sequence set forth by SEQ ID NOs: 7, 8, 10-52 or 57; or
(ii) a kynureninase polypeptide comprising a sequence having at least 95% identity to SEQ ID NOs: 7, 8, 10-52 or 57, wherein said polypeptide has kynureninase activity
and a pharmaceutically acceptable carrier.